Inflammation is a biological process of the immune system that enables survival through infection or bodily injury. Damaged cells, different pathogens, and toxic compounds can stimulate an inflammatory response that comprises of four components: the inducers, the sensors that detect the inducers, the mediators induced by the sensors, and the target tissues that are affected by these mediators. Both infectious and non-infectious agents (inducers) may activate distinct inflammatory signaling pathways (sensors).
Although acute inflammatory response is important for homeostasis, chronic and uncontrolled inflammatory processes can lead to cellular and tissue damage, and therefore they have been implicated in the development, progression, and prognosis of human cancers.
This Research Topic will focus on the inflammatory pathways involved in tumorigenesis, with an emphasis on inflammatory lipid and cytokine mediators and how they contribute to the induction of genomic instability, changes in epigenetic machinery, altered gene expression, increased proliferation, resistance to apoptosis, angiogenesis and immune escape of cancer cells.
It is well established that inflammatory processes are involved in the development and progression of different types of cancer. This Research topic collection will showcase the recent findings that explore the role of inflammatory mediators such as cytokines, chemokines, and lipid mediators (eicosanoids, sphingolipids prostaglandin) in the cellular and molecular mechanisms involved in oncoinflammation how they can be therapeutically leverage for the prognosis and treatments of cancer.
The increased evidence of involvement of these mediators in the development of tumors has led to clinical trials targeting signaling pathways induced by cytokines such as type I IFN, GM-CSF, G-CSF, interleukins (IL) 6, 7, 12, 15, 18, 21, chemokines CXCR2 and 4. Moreover, the targeting of immunosuppressive cytokines, such as IL-1, TGF-ß, and TNF, has been explored for the promotion of anti-tumor activity and enhance the efficacy of immunotherapies.
The submitted manuscripts to this Research Topic can be in the format of an Original Research article, Review, Mini Review, or Clinical Trial reports, and should focus on one of the following subtopics:
1) The role of cytokine and lipid mediators in the regulation of inflammatory pathways involved in tumor pathogenesis and progression;
2) Inflammasome signaling in cancer pathogenesis;
3) The use of oncoinflammatory cytokines and lipid mediators as biomarkers and new therapeutic targets in cancer.
Inflammation is a biological process of the immune system that enables survival through infection or bodily injury. Damaged cells, different pathogens, and toxic compounds can stimulate an inflammatory response that comprises of four components: the inducers, the sensors that detect the inducers, the mediators induced by the sensors, and the target tissues that are affected by these mediators. Both infectious and non-infectious agents (inducers) may activate distinct inflammatory signaling pathways (sensors).
Although acute inflammatory response is important for homeostasis, chronic and uncontrolled inflammatory processes can lead to cellular and tissue damage, and therefore they have been implicated in the development, progression, and prognosis of human cancers.
This Research Topic will focus on the inflammatory pathways involved in tumorigenesis, with an emphasis on inflammatory lipid and cytokine mediators and how they contribute to the induction of genomic instability, changes in epigenetic machinery, altered gene expression, increased proliferation, resistance to apoptosis, angiogenesis and immune escape of cancer cells.
It is well established that inflammatory processes are involved in the development and progression of different types of cancer. This Research topic collection will showcase the recent findings that explore the role of inflammatory mediators such as cytokines, chemokines, and lipid mediators (eicosanoids, sphingolipids prostaglandin) in the cellular and molecular mechanisms involved in oncoinflammation how they can be therapeutically leverage for the prognosis and treatments of cancer.
The increased evidence of involvement of these mediators in the development of tumors has led to clinical trials targeting signaling pathways induced by cytokines such as type I IFN, GM-CSF, G-CSF, interleukins (IL) 6, 7, 12, 15, 18, 21, chemokines CXCR2 and 4. Moreover, the targeting of immunosuppressive cytokines, such as IL-1, TGF-ß, and TNF, has been explored for the promotion of anti-tumor activity and enhance the efficacy of immunotherapies.
The submitted manuscripts to this Research Topic can be in the format of an Original Research article, Review, Mini Review, or Clinical Trial reports, and should focus on one of the following subtopics:
1) The role of cytokine and lipid mediators in the regulation of inflammatory pathways involved in tumor pathogenesis and progression;
2) Inflammasome signaling in cancer pathogenesis;
3) The use of oncoinflammatory cytokines and lipid mediators as biomarkers and new therapeutic targets in cancer.
